China-based Ascletis applied Monday to list on the Hong Kong Stock Exchange, the first company to take advantage of new rules that ease the way for pre-revenue biotechs to raise capital there.
Ascletis’ application may signal a flood of listings from biotechs looking to tap into a larger pool of investors at a relatively early stage in their development. That’s certain to include deep-pocketed generalists from China.
About the Author Reprints
